BridgeBio Oncology Therapeutics (BBOT) Profit After Tax (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Profit After Tax of -$42.1 million for Q1 2026, down 8.65% sequentially from -$38.8 million in Q4 2025, and down 90.52% YoY from -$444.4 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Profit After Tax (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$42.1 million in Q1 2026.
- Quarterly Profit After Tax fell 90.52% year-over-year to -$42.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.1 million (down 90.29% YoY) and the FY2025 annual result came in at -$134.0 million, down 80.35% from the prior year.
- Profit After Tax fell to -$42.1 million in Q1 2026 per BBOT's latest filing, from -$38.8 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$15.4 million in Q1 2024 and troughed at -$44.8 million in Q3 2025.
- A 3-year average of -$27.8 million and a median of -$22.1 million in 2025 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 30.3% in 2025, down 158.37% in 2025.
- Over 3 years, Profit After Tax stood at -$19.7 million in 2024, then tumbled by 96.6% to -$38.8 million in 2025, then retreated by 8.65% to -$42.1 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$42.1 million, -$38.8 million, and -$44.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -56.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.50 Mn |
| Mar 31, 2026 | -42.11 Mn |
| Dec 31, 2025 | -38.75 Mn |
| Sep 30, 2025 | -44.76 Mn |
| Jun 30, 2025 | -28.44 Mn |
| Mar 31, 2025 | -22.10 Mn |
| Dec 31, 2024 | -19.71 Mn |
| Sep 30, 2024 | -17.32 Mn |
| Jun 30, 2024 | -21.82 Mn |
| Mar 31, 2024 | -15.44 Mn |